Roche agreed to license an ALK7-targeting RNAi candidate from Rona Therapeutics, paying up to $100 million in upfront and early milestone payments for exclusive worldwide rights. Rona is also eligible for up to $1.06 billion in development, regulatory, and commercial milestones, along with tiered royalties. The deal reflects continuing pharma focus on cardiometabolic pathways where ALK7 biology is positioned to support fat loss while aiming to preserve lean mass. Roche framed the transaction as part of its broader search for mechanism-driven obesity and metabolic disease candidates. Rona’s program is delivered through an RNAi approach—an increasingly active modality as sponsors look for gene-silencing strategies that can be tuned by target tissue biology. For the biotech ecosystem, the agreement underscores how China-to-West licensing remains a fast route to expand modality and mechanism portfolios, especially in obesity where competition for differentiated pharmacology remains intense.